Business Wire

Cyolo Announces Integration with IBM’s On-Premise QRadar Security Solutions to Enhance Secure Remote Access Capabilities

4.9.2024 14:30:00 CEST | Business Wire | Press release

Share

Integration provides improved threat detection and analysis across critical industrial environments

Cyolo, the leading provider of secure remote access solutions for operational technology (OT) and industrial control systems (ICS), today announced its new integration with IBM Security’s on-premise QRadar Security Information and Event Management (SIEM) offerings. Together, Cyolo’s industry-leading PRO Secure Remote Access Platform (SRA) and IBM’s QRadar SIEM will enhance cybersecurity capabilities like threat detection and mitigation in critical OT/ICS environments.

The integration builds on IBM's previous investment in Cyolo during its series B funding round: In October 2022, IBM Ventures invested capital, cybersecurity expertise, and technical resources into Cyolo.

The integration comes at a time when Industry 4.0 is under heavy regulatory scrutiny, and organizations urgently need advanced security tools to remain compliant and protected. Security and operations teams are also overwhelmed by the expanding number of connected devices and volume of data in their environments, hindering their ability to manage risk and ensure operational efficiency. The current OT skills gap exacerbates these challenges, necessitating third-party contractors to assist with critical operations. This consequentially adds more risk as many CISOs do not have oversight of third-party activity in their enterprise’s network.

This new integration unlocks:

  • Actionable Intelligence: Even more efficient and secure analysis of critical OT environments is now possible, allowing swift data extraction from locations that previously required on-site access.
  • Improved Decision-Making: Greater visibility, control, and speed now enable even more informed decision-making in critical environments.

"Cyolo’s integration with IBM Security’s on-prem QRadar solution marks a significant milestone in OT security," said Joe O’Donnell, EVP Corporate Development and OT GM at Cyolo. "We're providing OT practitioners and industrial organizations with a powerful shield against evolving threats. As the world embraces Industry 4.0, our combined offering delivers not just superior security, but a pathway to operational resilience."

About Cyolo

Cyolo is a leading cybersecurity innovator dedicated to providing cutting-edge access solutions for all environments and deployment scenarios. With a focus on security, operational agility, and user experience, Cyolo is fostering a transition from merely enabling access to empowering operations, productivity, and compliance with its Cyolo PRO (Privileged Remote Operations) solution. To learn more, visit https://cyolo.io/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240904399632/en/

Contacts

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com

Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press release

Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne

Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that

2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press release

CEO of Zhong, one of YouTube’s most-watched creators with 70 million subscribers and 95 million followers on all platforms, joins program The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen

Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release

A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye